- Catnip Might Be Your Next Mosquito Repellent
- COVID Death Rates 10 Times Higher in Countries Where Most Are Overweight: Report
- Health Highlights: March 4, 2021
- She Barely Survived a Severe Form of COVID-19 Hitting Kids
- Add Sleep Woes to Long-Term Effects of Concussions
- Opioid Addiction Relapse May Be Different for Men, Women
- Is Your Teen Unmotivated at School? That Might Change
- Women With Type 1 Diabetes May Have Fewer Childbearing Years: Study
- Could Taking a Swing at Golf Help Parkinson’s Patients?
- New Coronavirus Variant Out of Brazil Now in 5 U.S. States
Aptiom Approved to Treat Seizures

MONDAY, Nov. 11Aptiom (eslicarbazepine acetate) has been approved by the U.S. Food and Drug Administration as an add-on drug to help treat adults with partial epileptic seizures.
Epilepsy, caused by abnormal activity in the brain’s nerve cells, is diagnosed in some 200,000 people annually in the United States, the agency said in a news release. So-called “partial” seizures are the most common type of seizure among people with epilepsy, triggering possible symptoms including repetitive movement of limbs, unusual behavior and convulsions.
Aptiom’s safety and effectiveness were evaluated in three clinical studies. The most common side effects noted were dizziness, drowsiness, nausea, headache, double vision and loss of coordination.
As with other anti-epileptic drugs, Aptiom may trigger thoughts of suicide in a small number of users, the FDA said. People who take the drug should contact a doctor immediately if they have thoughts of suicide, or worsening anxiety or depression, the agency warned.
Aptiom is marketed by Sunovion Pharmaceuticals, based in Marlborough, Mass.
More information
To learn more about epilepsy, visit the U.S. Centers for Disease Control and Prevention.
Source: HealthDay